Intercept Pharmaceuticals, Inc.
(NASDAQ : ICPT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MDCOMedicines Company
-1.61%47.7620.3%$139.37m
VRXValeant Pharmaceuticals International, Inc.
-2.11%23.2514.1%$136.81m
AMRNAmarin Corporation Plc Sponsored ADR
-0.24%16.711.8%$106.43m
PRGOPerrigo Co. Plc
0.04%55.986.8%$65.35m
JAZZJazz Pharmaceuticals Plc
-0.03%131.412.3%$62.65m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.99%141.016.2%$59.44m
SAGESAGE Therapeutics, Inc.
-0.69%159.798.6%$55.88m
MNKMallinckrodt Plc
10.20%3.3020.9%$44.18m
CTLTCatalent Inc
-1.19%51.332.4%$42.63m
ENDPEndo International Plc
-2.02%3.888.8%$39.68m
UTHRUnited Therapeutics Corporation
1.09%80.6914.3%$30.77m
PTLAPortola Pharmaceuticals, Inc.
0.72%30.686.7%$30.44m
ICPTIntercept Pharmaceuticals, Inc.
1.22%68.9016.9%$29.88m
ICLRICON Plc
0.25%149.924.1%$28.03m
AERIAerie Pharmaceuticals, Inc.
-4.41%22.096.8%$26.55m

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.